Kedan Lin

Kedan Lin has extensive work experience in the biopharmaceutical industry. Starting in 2000, they worked at Exelixis as a Research Scientist for four years before joining Celera Pharmaceuticals as a Staff Scientist from 2004 to 2006. Kedan then joined Genentech as a Senior Scientist, where they worked for ten years until 2016. Afterward, they served as the Director of Clinical Pharmacology at NGM Biopharmaceuticals from 2016 to 2018. From 2018 to 2020, they held the position of VP of Clinical Development and US Operation at Innovent Biologics and was later promoted to Senior Vice President until 2022. Kedan Lin is currently the SVP of US Operations at Harbour Biomed.

Kedan Lin completed their Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco, from 1994 to 2000. There is also mention of him obtaining another Ph.D., but no specific details are provided regarding the time period or field of study.